Biognosys
Biognosys is a Swiss proteomics company (majority-owned by Bruker) that provides DIA mass spectrometry CRO services, Spectronaut software, and peptide kits to pharmaceutical, biotech, and academic customers for biomarker discovery, drug development, and clinical research.
- Company typePrivate
- Founded2010
- HeadquartersSchlieren, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Biognosys does
Biognosys is a Swiss proteomics company, majority-owned by Bruker Corporation since January 2023, that provides next-generation proteomics solutions spanning contract research services, analytical software, and consumable kits to pharmaceutical, biotechnology, and academic customers. Its core technology combines Data Independent Acquisition (DIA) and Data Dependent Acquisition (DDA) mass spectrometry with proprietary Hyper Reaction Monitoring (HRM) methods and the P2 Plasma Enrichment workflow, enabling unbiased quantification of up to ~4,200 proteins in plasma, ~11,000 in biofluids, and ~13,800 in tissue or cell lines. The product portfolio centers on Spectronaut, a vendor-agnostic DIA proteomics software platform that also powers the TrueDiscovery, TrueTarget, and TrueSignature CRO service platforms, complemented by SpectroMine (DDA), SpectroDive (targeted), QuiC (free QC), OmicsFlow (automated sample processing), and peptide kits such as PQ500, iRT, and P2-iST.
The company monetizes through three primary streams: (1) CRO services delivered via direct enterprise sales to pharma and biotech clients for biomarker discovery, drug target validation, and clinical-trial pharmacoproteomics, sold on a project/multi-year basis with optional GLP/GCP compliance; (2) software licensing of Spectronaut and related products on both annual subscription and perpetual-plus-maintenance terms, distributed direct and through a reselling agreement with Thermo Fisher Scientific; and (3) consumable kits and reagents for in-house proteomics workflows, sold through the company website, a global distributor network, and, since 2024, NULISA assays from Alamar Biosciences. Distribution is anchored by the Bruker timsTOF partnership (giving preferred access to 4D-proteomics instruments), Thermo Fisher reselling, and US operations based in Newton, Massachusetts. The company is led by Co-Founder and CEO Dr. Oliver Rinner and reports a global footprint with 51-100 employees across Schlieren (Switzerland) and Newton, Massachusetts.
Biognosys firmographics
Firmographics- Name
- Biognosys
- Legal name
- Biognosys AG
- Website
- https://biognosys.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Biognosys is a Swiss proteomics company (majority-owned by Bruker) that provides DIA mass spectrometry CRO services, Spectronaut software, and peptide kits to pharmaceutical, biotech, and academic customers for biomarker discovery, drug development, and clinical research.
- Ownership category
- akta.pro rank
Biognosys industry classification
Industry- Product category
- Proteomics Software
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Proteomics & Mass Spectrometry Services (HLAGANAB)
- akta.pro secondary industries
- Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Proteomics & Biomarker Analytical Testing (HLAGADAG), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)
Keywords
Where Biognosys is headquartered
LocationHeadquarters
- HQ city
- Schlieren
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Biognosys business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- CRO Services: Contract research organization services providing proteomics analysis for pharma and biotech clients including TrueDiscovery, TrueTarget, and TrueSignature platforms. Services include biomarker discovery, drug discovery, and pharmacoproteomics for clinical trials.
- Software Licensing: Licensing of Spectronaut, SpectroMine, SpectroDive, and QuiC software for proteomics data analysis. Available as recurring licenses or perpetual licenses with annual maintenance fees.
- Kits and Reagents: Sale of peptide kits including PQ500 reference peptides for quantification, iRT kits for quality control, and sample preparation reagents for researchers conducting proteomics in-house.
- Method Transfer: Transfer of proprietary P2 Plasma Enrichment workflow to customers who wish to conduct the method in-house, including documentation, training, and initial materials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CRO Services - Project-based pricing |
| Unit Pricing | Pay-as-you-go | Product shipping fees |
| Subscription | Annual | Software - Recurring License Option |
| One time/ perpetual license | Multi-year contract | Software - Perpetual License Option |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Biognosys product offering
Product offeringCore offering
Biognosys develops and commercializes next-generation proteomics solutions comprising proprietary software platforms (Spectronaut, SpectroMine, SpectroDive, QuiC, OmicsFlow, Proteoverse) for mass spectrometry-based protein analysis, contract research organization services (TrueDiscovery, TrueTarget, TrueSignature) for biomarker discovery and drug target identification, and consumable peptide/reagent kits (PQ500 Reference Peptides, iRT Kit, P2 Plasma Enrichment, P2-iST) for sample preparation and assay calibration.
Product overview
Biognosys offers an integrated proteomics portfolio consisting of software products (Spectronaut® for DIA proteomics, SpectroMine™ for DDA proteomics, SpectroDive™ for targeted proteomics, QuiC™ for QC, OmicsFlow® for automated processing), peptide kits (PQ500™ Reference Peptides, iRT Kit, P2-iST), proprietary technologies (P2 Plasma Enrichment), and research service platforms (TrueDiscovery®, TrueTarget™, TrueSignature™). The software products form the analytical foundation, with Spectronaut serving as the core DIA platform that also powers the TrueDiscovery CRO services. The kit products enable researchers to perform proteomics in-house, while CRO services provide outsourced proteomics research capabilities. A partnership with Bruker enables integration with timsTOF mass spectrometry platforms and metabolomics services.
Differentiator
Problem solved
Functional benefit
Brands
- Spectronaut®: Vendor-agnostic software for DIA (Data Independent Acquisition) proteomics analysis, the leading software for next-generation proteomics.
- SpectroMine™
- SpectroDive™
- QuiC™
- OmicsFlow®
- TrueDiscovery®
- TrueTarget™
- TrueSignature™
- PQ500™
- Proteoverse®
- P2 Plasma Enrichment
- iRT Kit
- NULISA™
Products and services
- Spectronaut Flagship DIA proteomics analysis software for protein identification, quantification, and statistical analysis of mass spectrometry data, used by pharma, biotech, and academic researchers worldwide.
- SpectroMine DDA proteomics analysis software for protein identification and quantification from mass spectrometry data, supporting spectral library generation and routine discovery workflows.
- SpectroDive Targeted proteomics software for reproducible, high-throughput quantification of proteins and peptides using targeted mass spectrometry assays (e.g., PRM/SRM).
- QuiC Quality control software for monitoring and assessing the quality of mass spectrometry-based proteomics experiments.
- OmicsFlow Automated proteomics workflow software that orchestrates and streamlines multi-step data analysis pipelines for routine and high-throughput proteomics.
- Proteoverse Digital proteome data platform for managing, sharing, and exploring proteomics datasets across teams and projects.
- TrueDiscovery Contract research service providing unbiased, deep proteome profiling and biomarker discovery using Biognosys's DIA workflows and software, delivered to pharma, biotech, and academic customers.
- TrueTarget Contract research service for drug target identification and deconvolution using chemical proteomics and affinity-based mass spectrometry workflows.
- TrueSignature Contract research service for the development and validation of targeted biomarker signature panels using targeted mass spectrometry assays.
- PQ500 Reference Peptides Quantitative reference peptide kit providing internal standards for absolute and relative quantification in targeted mass spectrometry proteomics assays.
- iRT Kit Indexed Retention Time (iRT) reference peptide kit used for retention time calibration and scheduling in mass spectrometry proteomics experiments.
- P2 Plasma Enrichment Plasma sample preparation kit enabling high-throughput, reproducible plasma proteomics workflows for biomarker research.
- P2-iST Integrated sample preparation kit (P2-iST) for streamlined and reproducible proteomics sample processing workflows.
Quantifiable outcome
- 10% more protein groups and 11% more peptides identified with Spectronaut 21
- +3 more outcomes
Companies that use Biognosys
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Biognosys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature12 records
Biognosys partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- SISCAPA Assay TechnologiescoreCollaboration to develop ultra-sensitive targeted protein assays for clinical research. Biognosys uses its SISCAPA and TrueSignature targeted proteomics platforms to create assays for deployment in clinical trials providing pharmacodynamic readouts.
- Biocrates Life Sciences AGmajorPartnership to expand hybrid metabolomics offerings. Biognosys launched metabolomics/lipidomics services using Biocrates technology to complement its proteomics capabilities for multiomic drug discovery.
- The Michael J. Fox Foundation for Parkinson's ResearchcoreCollaboration to develop sensitive and quantitative biomarker assays for LRRK2, the most common genetic risk factor for late-onset Parkinson's disease. Supports MJFF's LITE initiative involving more than 50 academic, industry, and clinical partners using open-science approach.
- FreenomecorePartnership to combine Biognosys' protein quantification capabilities with Freenome's AI genomics platform for early-cancer detection and precision oncology. Integrates protein and cell-free DNA/RNA analysis for improved multi-analyte screening.
- Thermo Fisher ScientificmajorReselling agreement for Spectronaut proteomics software, making it directly available from Thermo Fisher Scientific alongside their mass spectrometry systems.
- Alamar BiosciencesmajorStrategic partnership to expand Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomics. NULISA assays now commercially available through Biognosys.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Biognosys competitors and assessment
Company assessmentBroad incumbents
- Thermo Fisher Scientific: Global mass spectrometry and life sciences instrument leader that resells Spectronaut and offers its own proteomics analysis pipelines. Comparable as both a distribution partner and a potential competitor for DIA software and proteomics services.
- Bruker Corporation: Biognosys' majority owner and timsTOF mass spectrometry platform provider. Operates broadly across proteomics instruments and 4D-proteomics workflows that directly underpin Biognosys' discovery services.
Direct peers
- Olink Holding: Provides proteomics biomarker discovery platforms (Proximity Extension Assay) targeting pharma/biotech translational research. Directly comparable in biomarker-focused proteomics services for clinical and discovery applications.
- SomaLogic (now part of Standard BioTools): Operates the SomaScan proteomics platform for large-scale biomarker discovery serving pharma and academic customers. Directly comparable as a high-throughput proteomics services and biomarker discovery competitor.
- PreOmics: Sample-preparation technology provider for mass spectrometry-based proteomics (iST kits), previously a codefendant with Biognosys in patent challenges. Directly comparable as a proteomics workflow reagent company serving the same MS-based research market.
- Alamar Biosciences: NULISA ultra-sensitive proteomics assay developer partnered with Biognosys for distribution. Comparable as an emerging proteomics biomarker assay company targeting biopharma translational and clinical research customers.
Emerging players
- Seer: Developer of the Proteograph next-generation proteomics platform using nanoparticle-based enrichment. Comparable as an emerging proteomics technology provider pursuing unbiased deep proteome profiling for biomarker and translational research.
- Evosep: Develops standardized LC-MS workflows for high-throughput proteomics. Comparable as a workflow technology provider enabling large-scale clinical proteomics, frequently used alongside DIA pipelines similar to Spectronaut.
- Quantum-Si: Developer of next-generation single-molecule protein sequencing technology aimed at proteomics research and biomarker discovery. Comparable as an emerging player pursuing deeper proteome coverage at scale.
Others
- Cell Signaling Technology: Major provider of antibodies and proteomics reagents serving the same MS-based and antibody-based research market. Comparable as an adjacent reagent/assay vendor with strong pharma/biotech relationships.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Biognosys social profiles
Digital presenceBiognosys compliance and trust
Trust signalCompliance2 records
Biognosys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biognosys leadership team
Management profileNumber of profiles
Profiles3 records
Biognosys subsidiaries and ownership
Company hierarchySubsidiaries1 record
Biognosys funding detail
Funding detailFunding overview
Funding rounds8 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biognosys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biognosys
What does Biognosys do?
Biognosys develops and commercializes next-generation proteomics solutions comprising proprietary software platforms (Spectronaut, SpectroMine, SpectroDive, QuiC, OmicsFlow, Proteoverse) for mass spectrometry-based protein analysis, contract research organization services (TrueDiscovery, TrueTarget, TrueSignature) for biomarker discovery and drug target identification, and consumable peptide/reagent kits (PQ500 Reference Peptides, iRT Kit, P2 Plasma Enrichment, P2-iST) for sample preparation and assay calibration.
Is Biognosys a public or private company?
Biognosys is a private company. It is classified as corporate owned and is currently operating.
When was Biognosys founded?
Biognosys was founded in 2010. It employs 51 to 100 people.
Where is Biognosys based?
Biognosys is headquartered in Schlieren, Switzerland, in the Europe region.
How does Biognosys make money?
Four revenue lines are on record. CRO Services are the primary driver. The others are software Licensing, kits and Reagents and method Transfer.
Who are Biognosys's main competitors?
Broad incumbents on record are Thermo Fisher Scientific and Bruker Corporation. Direct peers are Olink Holding, SomaLogic (now part of Standard BioTools), PreOmics and Alamar Biosciences. Emerging players are Seer, Evosep and Quantum-Si. Cell Signaling Technology is listed as an others.
Does Biognosys have an API?
No public API is recorded for Biognosys.
What industry is Biognosys in?
Biognosys's product category is Proteomics Software. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments. Its NAICS code is 621511 and its SIC code is 8071.